According to Hazelden Betty Ford, a neurostimulation device made by Spark Biomedical shows promise in helping adults and young adults emerge from addiction.
Final enrollment concludes for Spark Biomedical's pivotal study investigating a non-invasive, drug-free neurostimulation therapy aimed at improving treatment retention for adults with opioid use disorder.
The investment will support the company’s core areas of bioelectronic medicine, including neurological health, hemostasis, and women’s health.
